Webinar: Mouse Models to Investigate New Treatments for Inflammatory Disease
January 7, 2022
We’re pleased to continue our new webinar series informing and updating our network of research professionals. We invite you to join us to learn about the latest technological advances at Biocytogen and to engage with our expert scientists! Our webinar “Mouse Models to Investigate New Treatments for Inflammatory Disease” will be held on Jan 26, […]
Biocytogen/Eucure Biopharma Announce the Completion of First Patient Dosing for Phase II Clinical Trial of YH003 in Australia
December 10, 2021
Beijing, China, December 9, 2021/PRNewswire/ – Eucure Biopharma, a wholly owned subsidiary of Biocytogen, announced the first patient dosing for a phase II clinical trial of YH003 (anti-CD40 monoclonal antibody, mAb) (No. YH003004) in Australia. The open-label, multi-regional clinical trial (MRCT) will evaluate the efficacy and safety of YH003 in combination with Toripalimab (anti-PD-1 mAb) […]
2021 Highlights: Humanized Model Publications
December 8, 2021
We are proud to highlight our growing list of publications featuring off-the-shelf and customized mouse, rat, and cancer cell models in well-respected, high-impact journals. Featured below is a selection of publications throughout 2021 that used our humanized mouse models. Congratulations to our colleagues who have contributed to these exciting results! Humanized B-h4-1BB Mice Hurov K, Lahdenranta […]
Biocytogen/Eucure Biopharma Announce the Completion of First Patient Dosing for Phase I Clinical Trial of YH004 (Anti-4-1BB Monoclonal Antibody) in Australia
December 7, 2021
BEIJING, CHINA, December 7, 2021 – Eucure Biopharma, a wholly owned subsidiary of Biocytogen, announced the first patient dosing for a phase I clinical trial of YH004 (anti-4-1BB monoclonal antibody, mAb) (No. YH004002) in Australia. The study is an open-label, multi-center and classical dose-escalation phase I study of YH004 monotherapy or in combination with anti-PD-1 mAb. […]
Biocytogen/Eucure Biopharma’s YH001 (Anti-CTLA-4 Monoclonal Antibody) Approved for Phase II Multi-Regional Clinical Trial by China National Medical Products Administration
November 10, 2021
BEIJING, November 9, 2021 – Eucure Biopharma, a wholly owned subsidiary of Biocytogen dedicated to developing proprietary antibody drugs, announced that the China National Medical Products Administration (NMPA) has approved YH001 for phase II Multi-Regional Clinical Trials (MRCT) in China. This phase II, open-label, multi-center study (No. YH001004) will evaluate the safety and efficacy of YH001 in […]
Webinar: Investigating Inflammatory Disease using Humanized Cytokine Mice
November 9, 2021
Our webinar “Investigating Inflammatory Disease using Humanized Cytokine Mice” was live on Dec 1, 2021 at 1PM. In this webinar, we will: – Review the range of cytokines associated with various autoimmune and allergy related diseases – Describe some of the inflammatory disease models we have developed including asthma, atopic dermatitis, and psoriasis – Introduce […]
Biocytogen/Eucure Biopharma’s YH003 (Anti-CD40 Monoclonal Antibody) Approved for Phase II Multi-Regional Clinical Trial by China National Medical Products Administration
November 4, 2021
BEIJING, November 2, 2021 – Eucure Biopharma, a wholly owned subsidiary of Biocytogen dedicated to developing proprietary antibody drugs, announced that the China National Medical Products Administration (NMPA) has approved YH003 for phase II Multi-Regional Clinical Trials (MRCT) in China. NMPA has approved Eucure Biopharma to conduct a phase II MRCT: a phase II, open-label, multi-center study […]
Eucure Biopharma, a Subsidiary of Biocytogen, and TRACON Pharmaceuticals Announce Partnership for Development of Clinical Stage CTLA-4 Antibody YH001
October 12, 2021
YH001 is a potential best-in-class CTLA-4 antibody with enhanced ADCC and CDC effector functions YH001 is currently being dosed in multiple Phase 1 oncology trials sponsored by Eucure Biopharma in Australia and China TRACON intends to initiate a Phase 1 trial of YH001 in combination with envafolimab in soft tissue sarcoma as well as to […]
Biocytogen Announces Collaboration With Envigo To Distribute the B-NDG Triple Immunodeficient and Humanizable Mouse Model
September 28, 2021
BEIJING and BOSTON, Sept. 28, 2021 /PRNewswire/ — Biocytogen announces a collaboration with Envigo, a global organization offering the broadest range of research models and related services. The two companies are committed to supporting research applications of the triple immunodeficient B-NDG mouse. Envigo is the exclusive provider of B-NDG mice in the United States, Europe, and certain Asia-Pacific regions. The triple immunodeficient B-NDG mouse […]
Webinar: Advancing T cell Therapies Using B-hCD3 Mouse Models
September 28, 2021
We are pleased to launch a new webinar series! Our webinar “Advancing T cell Therapies Using B-hCD3 Mouse Models” was live on Oct 28 at 1PM. In this webinar, we will review and discuss in-depth: ● Current challenges in screening leads and evaluating antibody candidates developed for T cell-mediated immunotherapy ● Generation and validation data […]
